Anixa Biosciences Inc $ANIX

What the company doesAI summary of filing

Anixa Biosciences is a pre-revenue biotechnology company developing therapies and vaccines for cancer treatment and prevention. The company develops liraltagene autoleucel (lira-cel), a CAR-T cell therapy for ovarian cancer through its subsidiary Certainty Therapeutics, and is conducting a Phase 1 clinical trial in collaboration with the H. Lee Moffitt Cancer Center. The company also develops cancer vaccines targeting breast cancer and ovarian cancer through exclusive licenses from Cleveland Clinic, with the breast cancer vaccine having completed Phase 1 testing, and is pursuing additional vaccine discovery for lung, colon, and prostate cancers. The company expects to generate revenue by eventually licensing its technologies to large pharmaceutical companies, with no near-term revenue expected from its therapeutic or vaccine programs. [10-K 2026-01-12]

Segments: Lira-cel (CAR-T cell therapy for ovarian cancer), Breast cancer vaccine, Ovarian cancer vaccine, Cancer vaccine discovery program (lung, colon, prostate)